Praxis Precision Medicines, Inc. (($PRAX)) has held its Q2 earnings call. Read on for the main highlights of the call. Praxis Precision Medicines, ...

Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) soared 27% on Monday after the company released encouraging top-line ...

Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) (NASDAQ: PRAX). Such investors ...

US$6.60 loss per share (further deteriorated from US$4.58 loss in 1H 2024). AI is about to change healthcare. These 20 stocks ...

Praxis Precision Medicines Inc (PRAX) extends cash runway into 2028 while reporting significant seizure reduction and ...

RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in ...

About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by ...

Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study ...

--Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by ...

Praxis Precision Medicines ended the third quarters with just over $410 million after posting a net loss of $51.9 million for the third quarter. The company listed no long-term debt on the 10-Q it ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Praxis Precision Medicines, a clinical-stage, genetic neuroscience company, launched today with more than $100 million in financing since its inception from ...

Praxis reported a net loss of $69.3 million for the three months ended March 31, 2025, including $8.8 million of stock-based compensation expense, compared to $39.6 million for the three months ...